The use of CytoSorb® in a prasugrel‐loaded patient undergoing emergent coronary artery bypass graft surgery

Abstract

Abstract Patients with acute coronary syndrome (ACS), failed percutaneous coronary intervention (PCI) and with an indication for emergent coronary artery bypass graft surgery (CABG) are at an increased risk of perioperative bleeding. Integration of the CytoSorb® (CS) adsorber into the cardiopulmonary bypass appears to bind prasugrel and minimize the risk of perioperative bleeding.

Keywords

• coronary artery bypass graft surgery
• CytoSorb®
• perioperative bleeding
• prasugrel, multiplate, platelet inhibition